Key statistics
As of last trade, Akeso Inc (9926:HKG) traded at 102.90, 84.91% above the 52 week low of 55.65 set on Feb 13, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 102.20 |
|---|---|
| High | 104.90 |
| Low | 102.10 |
| Bid | 102.80 |
| Offer | 103.00 |
| Previous close | 103.70 |
| Average volume | 6.99m |
|---|---|
| Shares outstanding | 921.14m |
| Free float | 717.29m |
| P/E (TTM) | -- |
| Market cap | 96.90bn HKD |
| EPS (TTM) | -1.08 HKD |
Data delayed at least 15 minutes, as of Feb 13 2026 03:31 GMT.
More ▼
Press releases
- Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
- Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
- Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
- Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
